A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages?

tion improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant 2015; 30: 682–689 10. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009; 4: 1384–1387 11. Adamson JW. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chronic Kidney Dis 2009; 16: 76–82 12. den Hoedt CH, Bots ML, Grooteman MP et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 2014; 86: 423–432 13. Grooteman MP, van den Dorpel MA, Bots ML et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087–1096 14. Mazairac AH, Blankestijn PJ, Grooteman MP et al. The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. Nephrol Dial Transplant 2013; 28: 1865–1873 15. Del Vecchio M, Giordana G, Pedrini L et al. Elements for economic evaluation on online Hemodiafiltration (ol-HDF) versus standard Haemodialysis to treat patients with End-Stage Renal Disease (ESRD). Ital J Publ Health 2012; 9: S1–S50